Daily Anesthesiology Research Analysis
Three impactful studies span mechanistic, clinical, and systems research in anesthesiology and perioperative care. A mechanistic study identifies RIPK1→JAK1–STAT3→CXCL1 signaling in type II alveolar cells as a driver of neutrophil recruitment and lung injury in sepsis, with a selective RIPK1 inhibitor improving survival in mice. A network meta-analysis of 49 RCTs supports virtual reality and other digital tools to reduce pediatric perioperative anxiety and pain, while a 753,263-patient cohort su
Summary
Three impactful studies span mechanistic, clinical, and systems research in anesthesiology and perioperative care. A mechanistic study identifies RIPK1→JAK1–STAT3→CXCL1 signaling in type II alveolar cells as a driver of neutrophil recruitment and lung injury in sepsis, with a selective RIPK1 inhibitor improving survival in mice. A network meta-analysis of 49 RCTs supports virtual reality and other digital tools to reduce pediatric perioperative anxiety and pain, while a 753,263-patient cohort suggests sertraline may be the safest SSRI to initiate alongside oxycodone for overdose risk.
Research Themes
- Mechanistic targeting of sepsis-induced lung injury via RIPK1–JAK1–STAT3 in alveolar epithelium
- Digital health interventions (VR, 2D media, games) to reduce pediatric perioperative anxiety and pain
- Pharmacoepidemiology of opioid–antidepressant combinations and overdose risk mitigation
Selected Articles
1. RIPK1 Drives JAK1-STAT3 Signaling to Promote CXCL1-Mediated Neutrophil Recruitment in Sepsis-Induced Lung Injury.
This mechanistic study shows that RIPK1 activation in type II alveolar epithelial cells induces JAK1–STAT3 signaling, upregulates CXCL1, and drives neutrophil recruitment in sepsis-induced lung injury. Genetic and pharmacologic RIPK1 inhibition (including Compound 62) reduced inflammation and lung damage and improved survival in septic mice.
Impact: It identifies a cell-intrinsic epithelial inflammatory amplifier and a druggable pathway (RIPK1–JAK1–STAT3→CXCL1) with survival benefit in vivo, offering a precise therapeutic target for sepsis-induced lung injury.
Clinical Implications: While preclinical, RIPK1 inhibitors could be explored to limit neutrophil-driven lung injury in sepsis, and the findings reframe alveolar epithelium as an active inflammatory driver. This supports translational trials with pharmacodynamic biomarkers (CXCL1, STAT3 activation).
Key Findings
- RIPK1 activation occurs selectively in type II alveolar epithelial cells during sepsis.
- RIPK1 engages JAK1 to phosphorylate STAT3, promoting STAT3 binding to the Cxcl1 promoter and upregulating CXCL1.
- Genetic or pharmacologic RIPK1 inhibition reduced CXCL1, neutrophil infiltration, alveolar damage, and improved survival in septic mice.
- Compound 62, a selective RIPK1 inhibitor, attenuated systemic inflammation and preserved epithelial barrier integrity.
Methodological Strengths
- Integrative transcriptomic and proteomic analyses pinpointed downstream mediators (CXCL1).
- Convergent genetic and pharmacologic inhibition across in vivo models with survival endpoints.
Limitations
- Preclinical murine models; human validation of epithelial RIPK1 activation and pharmacodynamics is needed.
- Potential off-target or systemic effects of RIPK1 inhibition require safety profiling.
Future Directions: Translate findings to early-phase clinical trials of selective RIPK1 inhibitors in sepsis-induced lung injury with biomarker-guided patient selection; validate epithelial cell–specific signaling and CXCL1 dynamics in human biospecimens.
Sepsis-induced lung injury, characterized by unregulated inflammation and impaired alveolar epithelial integrity, significantly contributes to sepsis-related mortality. Although receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is critical in regulating necroptosis and inflammation, its precise contribution to sepsis-induced lung injury remains poorly understood. In this study, selective activation of RIPK1 in type II alveolar epithelial cells (AECs) is observed during sepsis. CXCL1 is identified as a critical downstream target of RIPK1 through integrative transcriptomic and proteomic analyses. Mechanistically, RIPK1 interacts with JAK1 to induce STAT3 phosphorylation, facilitate its nuclear translocation, and promote its binding to the Cxcl1 promoter, thereby upregulating its expression and driving excessive neutrophil recruitment. Genetic or pharmacological inhibition of RIPK1 attenuated CXCL1 production, neutrophil infiltration, and alveolar damage, improving survival in septic mice. Compound 62, a selective RIPK1 inhibitor, has demonstrated efficacy in attenuating systemic inflammatory cascades, preserving epithelial barrier integrity, and improving survival rates in mice. These findings establish RIPK1 as a therapeutic target in sepsis-induced lung injury and redefine alveolar epithelial cells as positive contributors to inflammatory amplification. This work advances precision strategies to mitigate sepsis-induced lung injury, addressing a critical unmet need in critical care medicine.
2. Digital Health Interventions in Pediatric Perioperative Care: A Network Meta-Analysis.
Across 49 randomized trials (n=4,535), virtual reality, 2D videos, and 2D games meaningfully reduced pediatric preoperative anxiety and postoperative pain versus standard care, with VR showing the largest effects and improved induction compliance. Certainty of evidence was generally moderate.
Impact: Provides comparative effectiveness evidence supporting scalable, nonpharmacologic digital interventions to improve pediatric perioperative experience, enabling guideline and pathway integration.
Clinical Implications: VR and 2D media can be implemented as first-line adjuncts to reduce anxiety and pain and improve induction compliance, potentially reducing sedative premedication use and recovery agitation.
Key Findings
- Virtual reality reduced preoperative anxiety (SMD −1.14) and postoperative pain (SMD −1.09) versus control with moderate certainty.
- 2D videos and 2D games also reduced anxiety and pain; VR had the greatest effect on induction compliance.
- Findings were consistent across multiple trials with frequentist network meta-analysis and GRADE assessment.
Methodological Strengths
- Network meta-analysis across 49 RCTs with random-effects modeling and GRADE.
- Comprehensive comparator set including pharmacologic (midazolam) and nonpharmacologic controls.
Limitations
- Heterogeneity in interventions, outcome measures, and trial quality; some nodes had low-certainty evidence.
- Limited data on emergence delirium and long-term outcomes.
Future Directions: Standardize outcome measures, evaluate implementation in diverse settings, and assess long-term behavioral and recovery endpoints and cost-effectiveness of digital perioperative programs.
IMPORTANCE: Pediatric surgical patients often face considerable perioperative challenges, including anxiety and pain. Digital health interventions offer promise, but their efficacy remains uncertain. OBJECTIVE: To compare the effects of digital health interventions in pediatric perioperative care. DATA SOURCES: PubMed, Embase, Web of Science, CENTRAL, and CINAHL databases were searched up to March 1, 2025. STUDY SELECTION: Randomized clinical trials (RCTs) involving pediatric patients (aged ≤18 years) undergoing surgery with general anesthesia, where digital technology was used as a distraction intervention. DATA EXTRACTION AND SYNTHESIS: A frequentist network meta-analysis with random-effects model was used to calculate standardized mean differences (SMDs) or mean differences (MDs) with 95% CIs. Interventions were ranked using P values, risk of bias assessed using the Cochrane risk of bias tool 2, and certainty of evidence rated using the Grading of Recommendations, Assessment, Development, and Evaluations framework. MAIN OUTCOMES AND MEASURES: Critical outcomes included pediatric preoperative anxiety, postoperative pain, emergence delirium, and induction compliance. Important but noncritical outcomes encompassed parental preoperative anxiety and postoperative satisfaction. RESULTS: Of 7734 RCTs screened, 49 were included involving 4535 youth (pooled mean age, 7.42 years; 95% CI, 6.85 to 7.99; 2989 [65.9%] male) with 7 interventions: virtual reality (VR), 2-dimensional (2D) games, 2D videos, interactive robots, midazolam, control (standard care), and enhanced control (eg, booklets). Compared to control, VR (SMD, -1.14; 95% CI, -1.54 to -0.74; moderate certainty), 2D videos (SMD, -1.08; 95% CI, -1.51 to -0.65; moderate certainty), 2D games (SMD, -1.02; 95% CI, -1.54 to -0.49; low certainty), and enhanced control (SMD, -0.83; 95% CI, -1.53 to -0.13; low certainty) reduced preoperative anxiety. VR (SMD, -1.09; 95% CI, -1.58 to -0.59; moderate certainty), 2D games (SMD, -0.87; 95% CI, -1.62 to -0.12; low certainty), and 2D videos (SMD, -0.56; 95% CI, -1.06 to -0.06; moderate certainty) reduced postoperative pain. VR showed the greatest effect on compliance (MD, -0.93; 95% CI, -1.62 to -0.24; moderate certainty). No significant differences compared to control. CONCLUSIONS AND RELEVANCE: This network meta-analysis of RCTs found that VR, 2D videos, and 2D games significantly reduced pediatric perioperative anxiety and pain and improved induction compliance. These findings support the use of digital health interventions in pediatric perioperative care and their broader clinical adoption.
3. Comparative Risks of Opioid Overdose in Patients on Oxycodone Initiating Selective Serotonin Reuptake Inhibitors.
In a 753,263-patient weighted cohort adding SSRIs to oxycodone, overdose incidence was low overall, but sertraline was associated with slightly lower overdose risk than citalopram, escitalopram, fluoxetine, and paroxetine. Results were adjusted using propensity score matching weights and Cox models.
Impact: Provides large-scale comparative safety data to inform SSRI selection when co-prescribing with oxycodone, addressing respiratory depression and overdose risk in perioperative and pain management populations.
Clinical Implications: When initiating an SSRI for patients on oxycodone, sertraline may be preferred to minimize overdose risk; monitor closely regardless, and avoid high-risk combinations where possible.
Key Findings
- Among 753,263 patients, 1,250 overdose events occurred; incidence rates 10.8–15.2 per 1,000 person-years across SSRIs.
- Compared with sertraline, citalopram (HR 1.24), escitalopram (HR 1.22), fluoxetine (HR 1.26), and paroxetine (HR 1.26) had slightly higher overdose risk.
- Propensity score matching weights used to balance confounders; results held over 365-day follow-up and on-treatment analyses.
Methodological Strengths
- Very large, national claims cohorts with propensity score matching weights and time-to-event modeling.
- Head-to-head comparative safety across multiple SSRIs with clinically meaningful outcome (overdose).
Limitations
- Residual confounding and misclassification inherent to claims data; no direct causality can be inferred.
- Findings may not generalize to non-oxycodone opioids or to populations outside insured US cohorts.
Future Directions: Prospective studies to validate mechanistic bases (e.g., CYP interactions, serotonergic respiratory effects), extend analyses to other opioids, and develop clinical decision support for safer antidepressant–opioid combinations.
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are often co-prescribed with oxycodone, yet may potentiate respiratory depression. We aimed to assess the comparative effects of SSRIs on opioid overdose when added to oxycodone. METHODS: Using US commercial and public health insurance claims data (2004 - 2020), we conducted a cohort study in adults who initiated SSRI while on oxycodone. We assigned patients to one of five exposures (sertraline, citalopram, escitalopram, fluoxetine, and paroxetine) and followed them for opioid overdose (hospitalization or emergency room visit) for 365 days and while they stayed on both oxycodone and index SSRI. We used propensity score matching weights to adjust for potential confounders and weighted Cox proportional hazard models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: Among 753,263 eligible individuals (mean age 46 years [SD 16]; 527,340 females [70%]), 221,792 initiated sertraline, 173,352 citalopram, 153,968 escitalopram, 126,954 fluoxetine, and 77,197 paroxetine. Overall, 1250 opioid overdose events occurred, with incidence rates ranging from 10.8 to 15.2 per 1,000 person-years across individual SSRIs. Weighted HRs, relative to sertraline, were 1.24 (95% CI = 1.04, 1.50) for citalopram, 1.22 (95% CI = 1.01, 1.47) for escitalopram, 1.26 (95% CI = 1.04, 1.53) for fluoxetine, and 1.26 (95% CI = 1.01, 1.57) for paroxetine. No differences were observed across SSRIs other than sertraline. CONCLUSIONS: In this study of individuals who added an SSRI to oxycodone, the incidence of opioid overdose was low. Patients who initiated sertraline experienced overdose at a slightly lower rate than patients who initiated other SSRIs.